奥浦迈涨2.09%，成交额4682.06万元，主力资金净流出574.03万元

Group 1 - The core viewpoint of the news is that Aopumai's stock has shown significant volatility, with a year-to-date increase of 47.96% but a recent decline in the last five and twenty trading days [2] - As of August 29, Aopumai's stock price was 53.68 CNY per share, with a market capitalization of 6.095 billion CNY [1] - The company reported a revenue of 178 million CNY for the first half of 2025, representing a year-on-year growth of 23.77%, and a net profit of 37.55 million CNY, up 55.55% year-on-year [2] Group 2 - Aopumai's main business revenue composition includes 87.34% from products, 12.53% from services, and 0.13% from other sources [2] - The company is categorized under the pharmaceutical and biotechnology industry, specifically in the sub-sector of biological products [2] - As of June 30, 2025, Aopumai had 3,212 shareholders, an increase of 6.11% from the previous period, with an average of 24,100 circulating shares per shareholder, a decrease of 5.76% [2][3] Group 3 - Aopumai has distributed a total of 147 million CNY in dividends since its A-share listing [3] - Among the top ten circulating shareholders, ICBC Frontier Medical Stock A increased its holdings by 1.25 million shares, while other significant shareholders maintained their positions [3]